The Types segmentation isolates four principal device families: Continuous Positive Airway Pressure (CPAP), Bi‑level Positive Airway Pressure (BiPAP), Auto‑adjusting Positive Airway Pressure (APAP), and Adaptive Servo‑Ventilation (ASV). CPAP machines remain the largest revenue driver, representing roughly 50 % of the market, owing to their status as the clinical first‑line therapy for obstructive sleep apnea and their comparatively lower unit cost. BiPAP devices, which deliver distinct inspiratory and expiratory pressures, capture about 25 % of sales, serving patients with comorbidities such as chronic obstructive pulmonary disease or central sleep apnea where pressure differentiation improves compliance. APAP units, capable of real‑time pressure modulation based on detected events, hold an estimated 20 % share, reflecting increasing clinician preference for personalized therapy and the premium pricing of algorithm‑driven technology. ASV, a niche but high‑margin segment (~5 %), addresses complex central sleep apnea syndromes and is primarily adopted in specialized sleep‑disorder centers. Together, these type categories constitute the market taxonomy that determines product development focus and pricing dynamics.